Dr. Eric D. Jacobsen, MD
Hematology & Oncology (Hematology & Oncology Physician)
44 Binney St, Dana 1b30, Dana-farber Cancer Institute
Boston, MA 02115
- Medicare participating
At a glance
- Medical school
- University of Connecticut School of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 300
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: University of Connecticut School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 219248
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Brigham and Women Faulkner Hospital Jamaica Plain, MA
- Cape Cod Hospital Hyannis, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
- Physicians of Cape Cod Hospital (334 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 300
- Services billed
- 549
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 344 | 206 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 80 | 22 |
| Telephone medical discussion with physician, 11-20 minutes | 20 | 19 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | 16 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Boston, MA | 33 |
| Prednisone Other prescribers in Boston, MA | 21 |
| Brukinsa (zanubrutinib) | 19 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Boston, MA | 18 |
| Cotellic (cobimetinib fumarate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $5,420 in total to this clinician.
| Merck Sharp & Dohme LLC | $5,062 |
|---|---|
| Adc Therapeutics America, Inc. | $358 |
| Consulting Fee | $5,000 |
|---|---|
| Food and Beverage | $420 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jul 23, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $5,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $178,588 in research payments for these studies, mostly to the institutions running them.
- Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Ipsen Biopharmaceuticals, Inc · Withdrawn · NCT06692452 - Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Daiichi Sankyo Inc. · Active, not recruiting · NCT04703192 - DS-3201b in Participants With Lymphomas
Daiichi Sankyo Inc. · Active, not recruiting · NCT02732275 - A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma
Genmab A/s
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.